Research programme: CNS disorder therapeutics - Autobahn Therapeutics
Latest Information Update: 12 Mar 2021
At a glance
- Originator Autobahn Therapeutics
- Class Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 19 Feb 2021 Early research in CNS disorders in USA (PO) (Autobahn Therapeutics pipeline, February 2021)